Application 021723
- Type
- NDA
- Sponsor
- CP PHARMS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LYRICA | PREGABALIN | CAPSULE; ORAL | 25MG | No | No |
| 002 | LYRICA | PREGABALIN | CAPSULE; ORAL | 50MG | No | No |
| 003 | LYRICA | PREGABALIN | CAPSULE; ORAL | 75MG | No | No |
| 004 | LYRICA | PREGABALIN | CAPSULE; ORAL | 100MG | No | No |
| 005 | LYRICA | PREGABALIN | CAPSULE; ORAL | 150MG | No | No |
| 006 | LYRICA | PREGABALIN | CAPSULE; ORAL | 200MG | No | No |
| 007 | LYRICA | PREGABALIN | CAPSULE; ORAL | 225MG | No | No |
| 008 | LYRICA | PREGABALIN | CAPSULE; ORAL | 300MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| pregabalin | PREGABALIN | Dr.Reddys Laboratories Inc | ceed457b-8f43-4021-fd70-071c96e09470 | 2025-05-20 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Cipla USA, Inc. | 17a8087c-579f-42de-ae92-006ea64def2a | 2025-05-01 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Exelan Pharmaceuticals Inc. | 3fdc6e94-2504-416c-81dd-2db9bc194ebb | 2025-05-01 | Warnings, Adverse reactions | PREGABALIN |
| Lyrica | PREGABALIN | Viatris Specialty LLC | d4734e7d-5079-455e-8ff5-8f4539c998a9 | 2025-04-15 | Warnings, Adverse reactions | Lyrica PREGABALIN |
| Pregabalin | PREGABALIN | Mylan Pharmaceuticals Inc. | ebe34db4-816d-4f0a-adbb-826693662754 | 2025-04-12 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Aphena Pharma Solutions - Tennessee, LLC | b1f4b888-ac88-4250-8db1-706e7cc01e93 | 2025-03-21 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Aphena Pharma Solutions - Tennessee, LLC | b0f34220-0657-4868-ae01-014f9300f622 | 2025-03-03 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Proficient Rx LP | 580955ba-86f6-4e86-b0fa-dd44e8828b0e | 2025-03-01 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Proficient Rx LP | a025e4fc-e0c1-4c5b-a1c8-bd8e578a737e | 2025-03-01 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Coupler LLC | 2ccc641e-6859-046e-e063-6294a90a5017 | 2025-01-28 | Warnings, Adverse reactions | PREGABALIN |
| PREGABALIN | PREGABALIN | Direct_Rx | 8efb9652-86b9-4cb5-e053-2995a90adac0 | 2025-01-22 | Warnings, Adverse reactions | PREGABALIN |
| PREGABALIN | PREGABALIN | Direct_Rx | 8ee9e08f-cf87-599c-e053-2995a90a563c | 2025-01-22 | Warnings, Adverse reactions | PREGABALIN |
| PREGABALIN | PREGABALIN | Direct Rx | d88925b8-9be6-d862-e053-2995a90a1612 | 2025-01-21 | Adverse reactions | PREGABALIN |
| PREGABALIN | PREGABALIN | Direct_Rx | 91cf12b1-e1a6-dbc2-e053-2a95a90a8d5d | 2025-01-17 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Preferred Pharmaceuticals, Inc. | 8c3aedae-9745-4f63-ad64-a643f0245418 | 2025-01-16 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Proficient Rx LP | 2b87989d-6411-4996-8f05-05806ab80525 | 2025-01-01 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Advanced Rx of Tennessee, LLC | afc89ca3-5597-1c75-e053-2a95a90a3ff2 | 2024-12-31 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Advanced Rx of Tennessee, LLC | afd59273-75d1-5f33-e053-2995a90ab25f | 2024-12-31 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Advanced Rx of Tennessee, LLC | afc8d9f1-df31-607b-e053-2995a90a028c | 2024-12-31 | Warnings, Adverse reactions | PREGABALIN |
| Pregabalin | PREGABALIN | Advanced Rx of Tennessee, LLC | afc8c76e-9b21-7ddb-e053-2a95a90ad736 | 2024-12-31 | Warnings, Adverse reactions | PREGABALIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.